Results of online modified Delphi panel to develop performance measures for IA (Round 3). Values are median (interquartile range).
| Performance Measure 1: Waiting times for rheumatologist consultation for patients with IA | ||||
| Variables | RA | AS | PsA | JIA |
| Scientific validity | 8 (8–9) | 7 (5–7) | 7 (6–8) | 7 (7–8) |
| Face validity | 8 (8–9) | 8 (7–8) | 8 (8–8) | 8 (8–9) |
| Control over measure | 6 (5–7)* | 6 (5–6)* | 6 (5–7)* | 7 (6–7) |
| Information availability | 6 (5–6)* | 5 (4–6)* | 5 (4–6)* | 6 (5–6)* |
| Information reliable and unbiased | 7 (6–7) | 6 (5–7)* | 6 (6–7)* | 7 (6–7) |
| Relevance | 9 (9–9) | 8 (8–9) | 9 (8–9) | 9 (9–9) |
| Likelihood of use | 9 (8–9) | 8 (7–9) | 8 (8–9) | 9 (8–9) |
| Performance Measure 2: Percentage of patients with IA seen by a rheumatologist | ||||
| Variables | RA | AS | PsA | JIA |
| Scientific validity | 8 (7–9) | 7 (7–8) | 8 (7–8) | 8 (8–9) |
| Face validity | 8 (8–9) | 8 (8–9) | 8 (8–9) | 8 (8–9) |
| Control over measure | 7 (6–7) | 6 (6–7)* | 7 (6–7) | 7 (6–8) |
| Information availability | 7 (7–8) | 7 (6–7) | 7 (6–7) | 7 (7–8) |
| Information reliable and unbiased | 7 (6–8) | 6 (5–7)* | 6 (5–7)* | 7 (6–8) |
| Relevance | 9 (8–9) | 8 (7–9) | 8 (7–9) | 9 (8–9) |
| Likelihood of use | 9 (7–9) | 8 (7–9) | 8 (7–9) | 9 (7–9) |
| Performance Measure 3: Percentage of patients with IA seen in yearly followup by a rheumatology team member | ||||
| Variables | RA | AS | PsA | JIA |
| Scientific validity | 8 (7–8) | 7 (7–8) | 7 (7–8) | 8 (7–8) |
| Face validity | 8 (8–9) | 8 (7–9) | 8 (7–9) | 9 (8–9) |
| Control over measure | 7 (6–7) | 7 (6–7) | 7 (6–8) | 7 (6–8) |
| Information availability | 8 (7–8) | 7 (6–8) | 7 (6–8) | 8 (7–8) |
| Information reliable and unbiased | 7 (6–8) | 7 (6–8) | 7 (6–7) | 7 (6–8) |
| Relevance | 9 (8–9) | 8 (7–9) | 8 (7–9) | 8 (8–9) |
| Likelihood of use | 8 (7–9) | 8 (7–9) | 8 (7–9) | 8 (8–9) |
| Performance Measure 4: Percentage of patients with RA treated with a DMARD | ||||
| Variables | Values | |||
| Scientific validity | 9 (8–9) | |||
| Face validity | 9 (8–9) | |||
| Control over measure | 6 (6–7)* | |||
| Information availability | 7 (6–8) | |||
| Information reliable and unbiased | 7 (6–8) | |||
| Relevance | 9 (8–9) | |||
| Likelihood of use | 8 (8–9) | |||
| Performance Measure 5: Time to DMARD therapy in RA | ||||
| Variables | Values | |||
| Scientific validity | 9 (8–9) | |||
| Face validity | 9 (8–9) | |||
| Control over measure | 6 (6–7)* | |||
| Information availability | 7 (6–7) | |||
| Information reliable and unbiased | 6 (6–7)* | |||
| Relevance | 9 (8–9) | |||
| Likelihood of use | 8 (8–9) | |||
| Performance Measure 6: Rheumatologist per capita | ||||
| Variables | Values | |||
| Scientific validity | 9 (8–9) | |||
| Face validity | 9 (8–9) | |||
| Control over measure | 6 (6–7)* | |||
| Information availability | 7 (6–7) | |||
| Information reliable and unbiased | 6 (6–7)* | |||
| Relevance | 9 (8–9) | |||
| Likelihood of use | 8 (8–9) | |||
↵* Ratings 4–6 indicate that the panelists were uncertain as to the validity, relevance, etc. of the candidate measure. Ratings 7–9 in bold face indicate that panelists rated these measures as having high validity, relevance, etc. IA: inflammatory arthritis; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; JIA: juvenile idiopathic arthritis; DMARD: disease-modifying antirheumatic drug.